Heparin

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

ME Therapeutics
ME TherapeuticsNEW YORK, NY
2 programs
2
Sodium Heparin UQ subcutaneous drug administrationPhase 11 trial
Sodium heparin UQ Intravenous drug administrationPhase 11 trial
Active Trials
NCT03113084SuspendedEst. Oct 2023
NCT03125187SuspendedEst. Nov 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ME TherapeuticsSodium Heparin UQ subcutaneous drug administration
ME TherapeuticsSodium heparin UQ Intravenous drug administration

Clinical Trials (2)

NCT03113084ME TherapeuticsSodium Heparin UQ subcutaneous drug administration

Study With Heparin Sodium in Subcutaneous Administration

Start: Aug 2022Est. completion: Oct 2023
Phase 1Suspended
NCT03125187ME TherapeuticsSodium heparin UQ Intravenous drug administration

Study With Heparin Sodium in Intravenous Administration

Start: Feb 2021Est. completion: Nov 2022
Phase 1Suspended

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space